ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.7% – Should You Sell?

ADMA Biologics Inc (NASDAQ:ADMA)’s stock price traded down 8.7% on Monday . The company traded as low as $16.54 and last traded at $16.3930. 1,020,203 shares changed hands during trading, a decline of 46% from the average session volume of 1,899,939 shares. The stock had previously closed at $17.95.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $28.50.

ADMA Biologics Trading Down 0.1%

The firm has a 50 day moving average price of $18.04 and a two-hundred day moving average price of $17.13. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.65 and a current ratio of 7.13. The firm has a market capitalization of $4.27 billion, a P/E ratio of 20.85 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The firm had revenue of $134.22 million during the quarter, compared to the consensus estimate of $131.20 million. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The business’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.15 EPS. On average, equities research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Institutional Trading of ADMA Biologics

Several large investors have recently made changes to their positions in the stock. State Street Corp grew its position in ADMA Biologics by 5.6% in the 2nd quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock worth $219,950,000 after purchasing an additional 637,727 shares during the last quarter. Geode Capital Management LLC raised its position in shares of ADMA Biologics by 4.3% during the second quarter. Geode Capital Management LLC now owns 5,913,121 shares of the biotechnology company’s stock valued at $107,691,000 after buying an additional 245,309 shares during the last quarter. Westfield Capital Management Co. LP bought a new stake in shares of ADMA Biologics in the third quarter valued at about $74,866,000. Dimensional Fund Advisors LP grew its position in ADMA Biologics by 0.7% during the third quarter. Dimensional Fund Advisors LP now owns 4,798,274 shares of the biotechnology company’s stock worth $70,343,000 after buying an additional 35,199 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in ADMA Biologics by 1.8% during the third quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock valued at $68,842,000 after acquiring an additional 84,934 shares during the period. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.